Replies to post #3007 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Toomanyjobs thanks for mentioning the price of EEMT. Pryzbyl is known for being conservative in his estimates. He predicted normalized annual sales of 340,000 prescriptions at net sales price of $250 a pop. This translates into $85 million per year for EEMT alone, most likely normalizing in Q3 when any forward purchases have worked their way through the system.

Scott Henry of Roth Capital Partners and Rohit Vanjani of Oppenheimer were probing the impact of the competitor who has possible capability to produce EEMT. According to Przybyl they have enough material to produce a 6 month supply capturing 50% of the market over 6 months at which point ANI will be the sole provider of EEMT. I figure they will assess sales of EEMT at $63.75 million in the first year followed by $85 million per year thereafter.

Once the analyst have done their fact checking and their preferential clients have jumped on board look for the average 1 year target price to climb close to $80.

Note: It will climb even further once more details on Teva products for release in Q4 are released.

In the short term, if forward purchases of EEMT for Q2 are consistent with Q4 results, I expect earnings in excess of $14 million for Q2.